Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Ahmed Kaseb, MD, on survival outcomes in the IMBRAVE 150 phase 3 study

Dr. Kaseb, Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, on the survival outcomes in the IMBRAVE 150 phase 3 study and whether it is compelling enough to be a new standard of care in the first line treatment of HCC

Tags: ASCO GI Conference CoverageLiver (includes HCC, Billiary Tract)

Published: 25 January 2020

Recent Videos

video

David Quinn, MD, explains the impact of data being presented at ASCO GU20 regarding neoadjuvant bladder cancer

Dr. Quinn, Associate Professor of Medicine, USC Norris Comprehensive Cancer Center, explains the impact of data being presented at ASCO ...

video

David Quinn, MD, on best utilization of stereotactic radiation in the management of advanced renal cell carcinoma patients

Dr. Quinn, Associate Professor of Medicine, USC Norris Comprehensive Cancer Center, discuses best utilization of stereotactic radiation in the management ...

video

David Quinn, MD, discusses Checkmate-214 investigating nivolumab + ipilimumab in advanced renal cell carcinoma patients

Dr. Quinn, Associate Professor of Medicine, USC Norris Comprehensive Cancer Center, on the results of long term follow up of ...

video

David Quinn, MD, describes if biomarkers help guide treatment in advanced renal cell carcinoma

Dr. Quinn, Associate Professor of Medicine, USC Norris Comprehensive Cancer Center, describes whether biomarkers are able to aid in guiding ...

video

Scott Tawaga, MD, on the study investigating Nadofaragene firadenovec in BCG unresponsive non muscle invasive bladder cancer

Dr. Tawaga, Medical Director of the Genitourinary Oncology Program at Weill Cornell Medicine and NewYork-Presbyterian, shares perspective on the study ...

video

Scott Tawaga, MD, explains intravesical therapies being developed given there is a BCG shortage

Dr. Tawaga, Medical Director of the Genitourinary Oncology Program at Weill Cornell Medicine and NewYork-Presbyterian, explains intravesical therapies being developed ...

video

Scott Tawaga, MD, shares results of phase 1 dose escalation study of 225Ac-J591 in metastatic prostate cancer patients

Dr. Tawaga, Medical Director of the Genitourinary Oncology Program at Weill Cornell Medicine and NewYork-Presbyterian, shares results of phase 1 ...

video

Tian Zhang, MD, on follow up investigation of Checkmate 025 in renal cell carcinoma patients

Dr. Zhang, Assistant Professor of Medicine, Duke University School of Medicine, shares results of the 5 year follow up of ...

video

Bradley McGregor, MD, on metastatic renal cell cancer patients whose cancer returns and were previously treated with I-O

Dr. McGregor, Clinical Director, Dana Farber Cancer Institute, discusses strategy when treating metastatic renal cell cancer patients whose cancer returns ...

video

Nicolas Salgia, BSc, on ways ethnicity impacts 1st line metastatic renal cell carcinoma patients receiving targeted therapy

Dr. Salgia, BSc, City of Hope, on the impact of ethnicity on outcomes in 1st line metastatic renal cell carcinoma ...

Related Videos

video-image

Michael Atkins, MD, shares exciting potential of current late-stage clinical studies in renal cell cancer patients

video-image

Robert Figlin, MD, on appropriate patient types to receive a TKI in the treatment of 1st line renal cell carcinoma patients

video-image

Nicolas Salgia, BSc, on ways ethnicity impacts 1st line metastatic renal cell carcinoma patients receiving targeted therapy

video-image

Daniel Petrylak, MD, expresses the efficacy of infigratinib in FGFR3-altered mUC patients

video-image

Robert Figlin, MD, shares exciting potential of current late-stage clinical studies in RCC patients

video-image

Bradley McGregor, MD, on metastatic renal cell cancer patients whose cancer returns and were previously treated with I-O

video-image

Daniel Petrylak, MD, shares potential efficacy when adding immunotherapy such as sip-T in mCRPC

video-image

Arlene Siefker-Radtke, MD, regarding the development of erdafitinib in bladder cancer

video-image

Tian Zhang, MD, on follow up investigation of Checkmate 025 in renal cell carcinoma patients

video-image

Daniel Petrylak, MD, explains the effect of second antigen spread in mCRPC patients

video-image

Arlene Siefker-Radtke, MD, shares the role of selecting mutations vs amplification for urothelial cancer treatment

video-image

Scott Tawaga, MD, shares results of phase 1 dose escalation study of 225Ac-J591 in metastatic prostate cancer patients

video-image

Anis Hamid, MD, describes real world impact of immunotherapy when added to oral therapies for advanced prostate cancer

video-image

Oliver Sartor, MD, on the exciting recent outcomes investigating Lu-177–PSMA in patients with advanced prostate cancer

video-image

Scott Tawaga, MD, explains intravesical therapies being developed given there is a BCG shortage

video-image

Anis Hamid, describes how RNA profiling guides treatment decisions about chemotherapy for metastatic prostate cancer

video-image

Tanya Dorff, MD, shares thoughts of the optimal sequence of atezolizumab and sip-T in mCRPC

video-image

Scott Tawaga, MD, on the study investigating Nadofaragene firadenovec in BCG unresponsive non muscle invasive bladder cancer

video-image

Yung Lyou, MD, on the relationship between hyperphosphatemia and infigratinib efficacy in urothelial carcinoma

video-image

Tanya Dorff, MD, on the future of cellular immunotherapy versus checkpoint inhibition in mPC